Global Prescription Hair Loss Hair Removal Drugs Market By Drug Type (Hair Loss Drugs (Minoxidil, Finasteride, Dutasteride, Platelet-Rich Plasma (PRP) Therapy, and Others)), Hair Removal Drugs(Eflornithine (Vaniqa), Laser-based Medications, and Others)), By Route of Administration (Topical Formulations, Oral Medications and Injectables), By Application (Chronic Hair Loss and Acute Hair Loss), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033
- Published date: Jan 2025
- Report ID: 138541
- Number of Pages: 318
- Format:
-
Quick Navigation
- Report Overview
- Key Takeaways
- Drug Type Analysis
- Route of Administration Analysis
- Application Analysis
- Distribution Channel Analysis
- Key Market Segments
- Drivers
- Restraints
- Opportunities
- Impact of Macroeconomic / Geopolitical Factors
- Latest Trends
- Regional Analysis
- Key Players Analysis
- Recent Developments
- Report Scope
Report Overview
Global Prescription Hair Loss Hair Removal Drugs Market size is expected to be worth around US$ 58.10 billion by 2034 from US$ 30.10 billion in 2024, growing at a CAGR of 6.8% during the forecast period 2025 to 2034.
The Prescription Hair Loss and Hair Removal Drugs Industry is a rapidly growing segment within the global healthcare and dermatology market, driven by increasing concerns about hair loss, unwanted hair, and cosmetic appearance. The industry primarily focuses on providing effective pharmaceutical solutions for conditions like androgenic alopecia (male and female pattern baldness), hirsutism, and other forms of hair loss. Key prescription treatments include Minoxidil, Finasteride, Dutasteride, and Eflornithine. These drugs are commonly prescribed in combination therapies to enhance effectiveness and reduce treatment times.
While hair loss treatments are widely popular, the hair removal segment, with products like Vaniqa (Eflornithine), targets unwanted hair growth, especially in women. The market is driven by factors such as rising awareness of available treatments, advancements in biotechnology, and the growing demand for aesthetic solutions. However, challenges such as side effects, long treatment durations, and cost remain key restraints. Despite these challenges, innovations in personalized medicine and combination therapies offer significant growth opportunities.
Key Takeaways
- In 2024, the market for Prescription Hair Loss Hair Removal Drugs generated a revenue of US$ 10 billion, with a CAGR of 6.8%, and is expected to reach US$ 58.10 billion by the year 2033.
- The type segment is divided into Hair Loss Drugs and Hair Removal Drugs with Hair Loss Drugs taking the lead in 2024 with a market share of 58.9%.
- Considering active Route of Administration, the market is divided into Topical Formulations, Oral Medications, and Injectables. Among these, Topical Formulations held a significant share of 48.6%.
- Furthermore, concerning the Application, the market is segregated into Chronic Hair Loss and Acute Hair Loss. The Chronic Hair Loss stands out as the dominant segment, holding the largest revenue share of 55.6% in the Prescription Hair Loss Hair Removal Drugs market.
- By Distribution channel, the market is classified into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Retail Pharmacies held a major share of 45.5%.
- North America led the market by securing a market share of 46.8% in 2024.
Drug Type Analysis
The Hair Loss Drugs segment is the largest and fastest-growing, owing to the higher prevalence of hair loss and the effectiveness of available treatments with 58.9% of market share. This segment includes treatments for androgenic alopecia and other hair loss conditions. Key drugs include Minoxidil (topical), Finasteride (oral), and Dutasteride (oral), which are primarily used for male and female pattern baldness. These drugs work by promoting hair growth or preventing further hair loss through various mechanisms such as stimulating blood flow (Minoxidil) or inhibiting the hormone DHT (Finasteride, Dutasteride).
Hair loss drugs are the leading segment in this market, driven by high demand for effective, long-term treatments and a growing consumer awareness of available therapies. For instance, in June 2023, Pfizer Inc. announced that the U.S. FDA has approved LITFULO (ritlecitinib), a once-daily oral treatment for individuals aged 12 and older with severe alopecia areata. The recommended dose for LITFULO is 50 mg.
Route of Administration Analysis
Topical Formulations is currently the dominating segment with 48.6% of market share. The Topical Formulations segment is the leading segment, driven by the popularity of Minoxidil and Eflornithine, which are easy to apply and effective for many users. This segment includes Minoxidil and Eflornithine (Vaniqa), which are applied directly to the scalp or skin. Topical treatments are popular due to their ease of use, targeted action, and lower risk of systemic side effects. Minoxidil, in particular, is a well-established and widely used topical treatment for hair loss in both men and women.
Hair loss treatments are often preferred in this form for their direct application and local effect. In February 2024, Pelage Pharmaceuticals has announced securing funding to start phase 2 trials of PP405, their innovative topical agent for androgenetic alopecia and other forms of hair loss. PP405 is a non-invasive, topical small molecule that targets the mitochondrial pyruvate carrier (MPC) to reactivate dormant hair follicle stem cells and stimulate hair growth, as stated by the company.
Application Analysis
Chronic Hair Loss segment is the leading segment which held 55.6% market share, driven by the high incidence of androgenic alopecia and the long-term need for effective treatments, making it a larger and more sustained market compared to acute hair loss. This is the most common form of hair loss and is typically treated with Minoxidil, Finasteride, and Dutasteride, which help slow down or prevent further hair loss and, in some cases, stimulate new hair growth.
Distribution Channel Analysis
The Retail Pharmacies segment is the largest and most widely used, primarily due to its accessibility, physical presence, and convenience for consumers seeking both over-the-counter and prescription hair loss and hair removal treatments. Retail Pharmacies is the dominant segment with 45.5% of market share. Retail pharmacies are convenient for customers seeking immediate access to treatments, often without the need for a doctor’s visit for prescriptions in some cases. This channel remains dominant due to the accessibility and wide availability of products.
Key Market Segments
Drug Type
- Hair Loss Drugs
- Minoxidil
- Finasteride
- Dutasteride
- Platelet-Rich Plasma (PRP) Therapy
- Others
- Hair Removal Drugs
- Eflornithine (Vaniqa)
- Laser-based Medications
- Others
Route of Administration
- Topical Formulations
- Oral Medications
- Injectables
Application
- Chronic Hair Loss
- Acute Hair Loss
Distribution channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Drivers
Increasing Prevalence of Hair Loss and Cosmetic Concerns
The rising prevalence of hair loss is one of the primary drivers for the Prescription Hair Loss and Hair Removal Drugs Market. Hair loss, particularly conditions like androgenic alopecia (male and female pattern baldness), is increasingly common due to factors like genetics, aging, hormonal imbalances, and lifestyle changes. For example, the Global Burden of Disease Study notes that hair loss is one of the most common conditions affecting people worldwide.
As per the data by National Alopecia Areata Foundation (NAAF), Alopecia areata is a common autoimmune skin disease. Approximately 7 million people in the U.S. and 160 million globally are affected by alopecia areata at some point in their lives. Currently, around 700,000 individuals in the U.S. have some form of this condition. Alopecia areata is an autoimmune disorder that leads to hair loss, and its prevalence highlights the importance of ongoing research and advancements in treatment options.
Additionally, the growing awareness around cosmetic appearance and the social acceptance of treatments has led many individuals to seek medical solutions to manage hair thinning or unwanted hair. In particular, both men and women are actively pursuing treatments to prevent further hair loss, regrow lost hair, or reduce excessive facial or body hair.
This heightened concern has led to a surge in demand for prescription treatments like Minoxidil, Finasteride, and Eflornithine, driving market growth. As people are becoming more open to seeking professional help, it has created a larger customer base for both hair loss and hair removal drugs, thus fueling the market expansion.
Restraints
Side Effects and Long Treatment Durations
One of the key restraints to the growth of the Prescription Hair Loss and Hair Removal Drugs Market is the side effects associated with many of these treatments, coupled with the lengthy treatment duration required for effective results. Medications like Finasteride and Minoxidil may cause side effects such as sexual dysfunction, scalp irritation, dizziness, and unwanted hair growth in non-target areas. These side effects can lead to patient non-compliance or discontinuation of treatment, particularly when the perceived benefits are slow or minimal in the initial phases.
Additionally, hair restoration drugs generally require prolonged use (typically 6–12 months) before noticeable effects appear, which can be discouraging for patients who seek faster results. For patients, the inconvenience of long-term commitment, coupled with potential side effects, can limit the effectiveness of these drugs. This hesitancy in long-term adoption of treatment regimens acts as a significant barrier to market growth, limiting the ability of companies to fully capitalize on the growing demand for hair loss and hair removal solutions.
Opportunities
Advancements in Personalized Medicine
The field of personalized medicine presents a significant opportunity for the Prescription Hair Loss and Hair Removal Drugs Market. Advances in genetic testing and biotechnology are enabling more tailored treatments based on individual genetic profiles, making it possible to offer highly targeted therapies for hair loss or unwanted hair.
For instance, personalized treatments could be developed by analyzing genetic markers that influence the effectiveness of hair growth drugs like Finasteride or Minoxidil. This approach could improve the precision of hair loss treatments, making them more effective and reducing the occurrence of side effects. Additionally, personalized therapies could help predict the onset of hair loss, allowing for earlier intervention and potentially better outcomes.
Companies investing in genetic diagnostics and biomarker-driven drug development could provide a competitive edge in this market. The shift towards personalized medicine also aligns with the growing consumer demand for solutions that address their specific needs and offer more efficient, customized treatment options, which can drive greater adoption of hair loss drugs and treatments.
Impact of Macroeconomic / Geopolitical Factors
Economic conditions, such as recession or inflation, can affect consumer spending on non-essential treatments, including those for hair loss and cosmetic concerns. During economic downturns, people may prioritize essential healthcare over aesthetic treatments, leading to reduced demand. Conversely, economic growth may increase disposable income, boosting demand for these products.
Geopolitical instability, such as trade restrictions, regulatory changes, or global supply chain disruptions, can affect the availability and pricing of active ingredients or finished products. For example, trade tensions may result in delays or price increases, impacting market dynamics. Additionally, political instability in certain regions may disrupt the distribution of hair loss or hair removal medications, affecting global sales.
Latest Trends
Rise of Combination Therapies
One of the most prominent trends in the Prescription Hair Loss and Hair Removal Drugs Market is the increasing use of combination therapies. Rather than relying on a single medication, more clinicians are recommending combination treatments to boost the efficacy of hair restoration and hair removal. For instance, combining Minoxidil (a topical vasodilator) with Finasteride (an oral 5-alpha-reductase inhibitor) can lead to better outcomes for male pattern baldness, as both drugs address hair loss through different mechanisms.
Similarly, some dermatologists are incorporating Platelet-Rich Plasma (PRP) therapy with drug treatments to enhance hair growth by stimulating the body’s natural healing processes. The combination of oral drugs, topical treatments, and advanced therapies (like PRP or low-level laser therapy) has been shown to improve results more quickly, which is appealing to patients seeking faster, more noticeable changes.
Additionally, combining different approaches can help target multiple causes of hair loss (e.g., hormonal imbalances, inflammation, and poor blood circulation), making combination therapies an effective and growing trend in the market. In October 2023, Bausch Health Companies Inc. and its dermatology division, Ortho Dermatologics, announced that the U.S. FDA has approved their New Drug Application for CABTREO™ (clindamycin phosphate, adapalene, and benzoyl peroxide) Topical Gel 1.2%/0.15%/3.1%. This topical treatment is indicated for acne vulgaris in patients aged twelve and older.
Regional Analysis
North America is leading the Prescription Hair Loss Hair Removal Drugs Market
The North American Prescription Hair Loss and Hair Removal Drugs Market is one of the largest and most dynamic regions globally holding 46.8% market share in 2024, driven by high consumer demand for aesthetic treatments and the increasing prevalence of hair loss conditions such as androgenic alopecia. The market is primarily fueled by the United States, where advanced healthcare infrastructure, high disposable income, and widespread awareness about hair loss treatments contribute to its growth. Minoxidil, Finasteride, and Eflornithine (Vaniqa) are among the most commonly prescribed medications for hair loss and hair removal in the region.
The rise of telemedicine and online pharmacies has further boosted market growth, offering consumers easier access to prescription medications. Additionally, advancements in biotechnology and personalized treatments are opening up new opportunities for the development of more effective solutions.
In July 2024, Sun Pharmaceutical Industries Limited, along with its subsidiaries and associate companies, announced that the U.S. FDA has approved LEQSELVI™ (deuruxolitinib) 8 mg tablets for treating severe alopecia areata in adults. However, high treatment costs and regulatory hurdles remain challenges. Despite this, North America remains a dominant market due to innovation and strong demand for cosmetic procedures.
Key Regions and Countries
North America
- US
- Canada
Europe
- Germany
- France
- The UK
- Spain
- Italy
- Russia
- Netherland
- Rest of Europe
Asia Pacific
- China
- Japan
- South Korea
- India
- Australia
- New Zealand
- Singapore
- Thailand
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Rest of MEA
Key Players Analysis
The Prescription Hair Loss Hair Removal Drugs Market is highly competitive, with a variety of companies focusing on innovation, regulatory approvals, and consumer trust to capture market share. Key players include Pfizer Inc., Johnson & Johnson, Eli Lilly and Co., Bayer AG, Merck & Co., Inc., Reviva Pharmaceuticals, Sandoz (a Novartis division), Taro Pharmaceutical Industries, Viatris, Dr. Reddy’s Laboratories, Solvay Pharmaceuticals (now part of AbbVie), Lumenis, Almirall S.A., Therapure Biopharma, Medytox, Aclaris Therapeutics, Perrigo Company, Medycann, Endo International, Purdue Pharma, and Other Prominent Players.
Pfizer has made significant strides in the hair loss treatment sector, particularly with its recent developments surrounding alopecia areata, an autoimmune condition that leads to hair loss. The company’s leading product in this area is Litfulo (ritlecitinib), which has garnered attention for its efficacy and innovative approach to treatment. Moreover, Eli Lilly and Co. has made significant advancements in the hair loss treatment sector, particularly with its product Olumiant (baricitinib), which has been approved for treating severe alopecia areata.
Top Key Players
- Pfizer Inc.
- Johnson & Johnson
- Eli Lilly and Co.
- Bayer AG
- Merck & Co., Inc.
- Reviva Pharmaceuticals
- Sandoz (a Novartis division)
- Taro Pharmaceutical Industries
- Viatris
- Reddy’s Laboratories
- Solvay Pharmaceuticals (now part of AbbVie)
- Lumenis
- Almirall S.A.
- Therapure Biopharma
- Medytox
- Aclaris Therapeutics
- Perrigo Company
- Medycann
- Endo International
- Purdue Pharma
- Otheer Prominent Players
Recent Developments
- In November 2024, the U.S. FDA approved LEQSELVI™ (deuruxolitinib) for alopecia areata, marking it as the third treatment approved for adults with severe cases. However, this approval has led to a legal dispute between Sun Pharmaceutical Industries, Ltd., the manufacturer of LEQSELVI, and Incyte Corporation, the patent holder for a similar drug, ruxolitinib.
- In May 2024, Soterios Pharma, a privately held clinical-stage pharmaceutical company, announced positive topline results from its Phase II trial evaluating STS-01 for the treatment of mild to moderate alopecia areata (AA). The randomized, placebo-controlled, multi-dose study demonstrated that STS-01 significantly improved hair regrowth and met multiple secondary endpoints.
- In May 2024, Researchers from MIT, Brigham and Women’s Hospital, and Harvard Medical School have developed a promising new treatment for alopecia areata, an autoimmune disorder that causes hair loss. The innovative microneedle patch delivers immune-regulating molecules designed to retrain T cells to stop attacking hair follicles, thus promoting hair regrowth. This up-close view of the microneedles shows the intricate design that makes this breakthrough possible.
Report Scope
Report Features Description Market Value (2024) US$ 30.10 billion Forecast Revenue (2033) US$ 58.10 billion CAGR (2025-2034) 6.8% Base Year for Estimation 2024 Historic Period 2020-2024 Forecast Period 2025-2034 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered By Prescription Hair Loss Hair Removal Drugs Market By Drug Type (Hair Loss Drugs (Minoxidil, Finasteride, Dutasteride, Platelet-Rich Plasma (PRP) Therapy, and Others)), Hair Removal Drugs(Eflornithine (Vaniqa), Laser-based Medications, and Others)), By Route of Administration (Topical Formulations, Oral Medications and Injectables), By Application (Chronic Hair Loss and Acute Hair Loss), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) Regional Analysis North America – US, Canada; Europe – Germany, France, The UK, Spain, Italy, Russia, Netherlands, Rest of Europe; Asia Pacific – China, Japan, South Korea, India, Australia, New Zealand, Singapore, Thailand, Vietnam, Rest of APAC; Latin America – Brazil, Mexico, Rest of Latin America; Middle East & Africa – South Africa, Saudi Arabia, UAE, Rest of MEA Competitive Landscape Pfizer Inc., Johnson & Johnson, Eli Lilly and Co., Bayer AG, Merck & Co., Inc., Reviva Pharmaceuticals, Sandoz (a Novartis division), Taro Pharmaceutical Industries, Viatris, Dr. Reddy’s Laboratories, Solvay Pharmaceuticals (now part of AbbVie), Lumenis, Almirall S.A., Therapure Biopharma, Medytox, Aclaris Therapeutics, Perrigo Company, Medycann, Endo International, Purdue Pharma, and Other Prominent Players Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) Prescription Hair Loss Hair Removal Drugs MarketPublished date: Jan 2025add_shopping_cartBuy Now get_appDownload Sample -
-
- Pfizer Inc Company Profile
- Johnson & Johnson
- Eli Lilly and Co.
- Bayer AG Company Profile
- Merck & Co., Inc.
- Reviva Pharmaceuticals
- Sandoz (a Novartis division)
- Taro Pharmaceutical Industries
- Viatris
- Dr. Reddys Laboratories Ltd Company Profile
- Solvay Pharmaceuticals (now part of AbbVie)
- Lumenis
- Almirall S.A.
- Therapure Biopharma
- Medytox
- Aclaris Therapeutics
- Perrigo Company
- Medycann
- Endo International
- Purdue Pharma
- Otheer Prominent Players
- settingsSettings
Our Clients
Kickstart 2025 with Exclusive Savings
Single User
$6,000
$3,999
USD / per unit
save 24%
|
Multi User
$8,000
$5,999
USD / per unit
save 28%
|
Corporate User
$10,000
$6,999
USD / per unit
save 32%
|
|
---|---|---|---|
e-Access | |||
Report Library Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 3,999) | Buy Now ($ 5,999) | Buy Now ($ 6,999) |